Retatrutide research peptide is supplied to qualified Canadian institutions as a characterized laboratory material for in vitro receptor-pharmacology and analytical method development. The compound is a synthetic peptide described in the peer-reviewed literature as a single-molecule agonist at GIP, GLP-1, and glucagon receptors (LY3437943).

In vitro, it is used when an experimental design must occupy those three incretin-family receptors with one reference ligand, for example in transfected-receptor assays that record second-messenger readouts against single-receptor agonists. This listing describes receptor pharmacology in experimental systems only.

The material is offered as a lyophilized vial. PubChem identity for the full structure is pending lot documentation; use the certificate of analysis for mass and purity. Store lyophilized at −20 °C, protected from light, and handle under the receiving institution's chemical-hygiene plan.

Lots are sourced from a GMP-aligned peptide manufacturing partner and released against the stated HPLC purity for that lot (≥99% by HPLC, lot-specific). Identity, chromatographic purity, and related analytical results are documented on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.